Abstract 1972: Clinical impact of 6q deletion patterns in prostate cancer.

Deletions of chromosome 6q12-22 represent the second common deletion in prostate cancer. Although most of these deletions are large and span > 50 megabases, a minimal deleted region containing 3-4 megabases was described at 6q15. MAP3K7 (at 6q15) was suggested as a potential target gene in this area. Based on the hypothesis, that large 6q deletions compromising a multitude of genes may have a different impact on the biology of prostate cancer cells than small circumscribed 6q15 deletions, a tissue microarray (TMA) containing over 7000 prostate cancers was analyzed by fluorescence in situ hybridization (FISH). All cancers were analyzed with probes for 6q12, 6q14, 6q15 (MAP3K7), 6q16, and 6q22. 3888 tumors were interpretable for all 5 probes including 463 (10.6%) showing a 6q deletion. 6q deletions were tightly linked to a negative ERG status with 15.6% deletions in ERG negative and 5.8% deletions in ERG positive cancers (p Citation Format: Martina Kluth, Nina Amschler, Anna Heinl, Simon Jung, Ronald Simon, Thorsten Schlomm, Guido Sauter, Sarah Jane Pauline Minner. Clinical impact of 6q deletion patterns in prostate cancer. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1972. doi:10.1158/1538-7445.AM2013-1972